Ebglyss Side Effects

Generic name: lebrikizumab

Medically reviewed by Drugs.com. Last updated on Apr 10, 2025.

Note: This document provides detailed information about Ebglyss.

Applies to lebrikizumab: parenteral prefilled pen or syringe Side Effects associated with lebrikizumab. Some dosage forms listed on this page may not apply specifically to the brand name Ebglyss.

Applies to lebrikizumab: parenteral prefilled pen or syringe.

Side effects include:

Most common (≥1%) adverse reactions were conjunctivitis, injection site reactions, herpes zoster.

For healthcare professionals

Applies to lebrikizumab: subcutaneous solution.

Dermatologic adverse events

• Uncommon (up to 1%): Herpes zoster^[Ref]

Hematologic

• Uncommon (0.1% to 1%): Eosinophilia^[Ref]

Local

• Common (1% to 10%): Injection site reaction^[Ref]

Ocular

• Common (1% to 10%): Conjunctivitis
• Uncommon (0.1% to 1%): Keratitis^[Ref]

See also:

Further information

Ebglyss side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer